(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of -1.63% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 5.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 125.98%.
Harvard Bioscience's revenue in 2025 is $88,750,000.On average, 1 Wall Street analysts forecast HBIO's revenue for 2025 to be $3,887,573,585, with the lowest HBIO revenue forecast at $3,887,573,585, and the highest HBIO revenue forecast at $3,887,573,585.
In 2026, HBIO is forecast to generate $4,252,729,409 in revenue, with the lowest revenue forecast at $4,252,729,409 and the highest revenue forecast at $4,252,729,409.